Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S ZYRTEC HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S ZYRTEC HIVES RELIEF.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CHILDREN'S ZYRTEC HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. It also inhibits eosinophil chemotaxis and mast cell mediator release.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
For adults, the recommended dose of cetirizine (active ingredient in Children's Zyrtec Hives Relief) is 10 mg orally once daily. Route: oral. Frequency: once daily.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life is 8-11 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may increase to 20-30 hours requiring dose adjustment.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Renal excretion accounts for approximately 70% of the administered dose, primarily as unchanged drug via tubular secretion. Fecal elimination is about 10% with the remainder metabolized.
Category A/B
Category C
Antihistamine
Antihistamine